Back

GC Biopharma wins approval for Phase 2/3 high-immunogenicity flu vaccine trial

Verifying
  • GC Biopharma won approval to begin Phase 2/3 testing of GC3114B.
  • GC3114B targets people aged 65 and over in the Phase 2 trial.
  • South Korea is reviewing high-immunogenicity vaccines for inclusion in its NIP.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.